Stockscreener 앱 받기
0.5017
5.38%
-0.0285
전일 마감가:
$0.5302
열려 있는:
$0.5273
하루 거래량:
639.49K
Relative Volume:
1.21
시가총액:
$46.53M
수익:
$2.24M
순이익/손실:
$-136.67M
주가수익비율:
-0.2191
EPS:
-2.29
순현금흐름:
$-102.08M
1주 성능:
-7.72%
1개월 성능:
-9.57%
6개월 성능:
-63.91%
1년 성능:
-84.07%
1일 변동 폭
$0.498
$0.5273
1주일 범위
$0.498
$0.57
52주 변동 폭
$0.3418
$3.70
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
IPSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5017 | 46.53M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Is it possible to buy Century Therapeutics Inc(IPSC) shares at a good price now? - uspostnews.com
Century Therapeutics Inc (IPSC): A Sitting Duck With -825.93% Upside Potential - Stocksregister
H.C. Wainwright maintains Buy rating on Century Therapeutics stock - Investing.com
Century Therapeutics Inc (IPSC)’s financial ratios: A comprehensive overview - DWinneX
H.C. Wainwright maintains Buy rating on Century Therapeutics stock By Investing.com - Investing.com UK
Century Therapeutics Inc [IPSC] Stock sold by Insider Pfeiffenberger Brent for $1375.0 - knoxdaily.com
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MSN
Century Therapeutics to Host Live Chat on Preclinical Cell Therapy Programs Targeting Autoimmune Diseases and Cancer - Nasdaq
Century Therapeutics to Host Live Fireside Chat Focused on - GlobeNewswire
Century Therapeutics Unveils Next-Gen Cell Therapy Pipeline for Cancer and Autoimmune | IPSC Stock News - Stock Titan
American Century Companies Inc. Buys Shares of 105,337 Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
American Century Companies Inc. Invests $231,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Sei Investments Co. Purchases New Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
American Century Companies Inc. Boosts Holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) - Defense World
American Century Companies Inc. Invests $474,000 in CARGO Therapeutics, Inc. (NASDAQ:CRGX) - Defense World
American Century Companies Inc. Acquires 4,547 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
American Century Companies Inc. Purchases 13,916 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
American Century Companies Inc. Has $696,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Bought by American Century Companies Inc. - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Buys 24,090 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Defense World
HC Wainwright Issues Positive Forecast for IPSC Earnings - Defense World
American Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
American Century Companies Inc. Has $3.36 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
American Century Companies Inc. Buys 1,622 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
American Century Companies Inc. Purchases 31,251 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
HC Wainwright Issues Pessimistic Forecast for Century Therapeutics (NASDAQ:IPSC) Stock Price - Defense World
H.C. Wainwright cuts Century Therapeutics target to $2 By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Sold by American Century Companies Inc. - Defense World
American Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by American Century Companies Inc. - Defense World
Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
What is Chardan Capital’s Estimate for IPSC FY2025 Earnings? - Defense World
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital - Defense World
William Blair Issues Optimistic Forecast for IPSC Earnings - The AM Reporter
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Q1 EPS Estimate for Century Therapeutics Boosted by Analyst - Defense World
Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating - MarketScreener
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Guggenheim Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - Defense World
Piper Sandler Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00 - Defense World
Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating By Investing.com - Investing.com Canada
What is William Blair’s Estimate for IPSC Q3 Earnings? - Defense World
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Century Therapeutics Reports 2024 Financial Results and Strategic Updates - TipRanks
Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating - Marketscreener.com
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Century Therapeutics Inc 주식 (IPSC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | See Remarks |
Mar 10 '25 |
Sale |
0.61 |
2,360 |
1,451 |
272,573 |
| Farid Adrienne | Chief Operations Officer |
Mar 10 '25 |
Sale |
0.61 |
2,359 |
1,451 |
131,717 |
| Carr Douglas | SVP Finance & Operations |
Mar 10 '25 |
Sale |
0.61 |
1,240 |
763 |
315,556 |
0.24%
36.06%
자본화:
|
볼륨(24시간):